MHRA grants approval for AstraZenecas Evusheld in the UK
It is the first antibody combination treatment authorised for use before exposure to COVID-19 infection in order to prevent disease licensed in the UK AstraZeneca (AZ) has announced that its antibody combination treatment Evusheld (tixagevimab co-packaged with cilgavimab) has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).
It is the first antibody combination for pre-exposure prophylaxis (PrEP) against COVID-19 to be licensed in the UK.
The treatment is authorised for use in adults who are not currently infected with
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!